Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. UFP Industries, Inc.

11.5% sales growth and 17.24% return on equity

UFP Industries, Inc., through its subsidiaries, designs, manufactures, and markets wood and wood-alternative products in North America, Europe, Asia, and Australia.

UFP Industries, Inc.’s sales growth this year is anticipated to be 12.2% and 2% for next year.

Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 4.76B for the twelve trailing months.

UFP Industries, Inc.’s sales growth for the next quarter is 11.5%. The company’s growth estimates for the present quarter and the next is 19.7% and 15.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.24%.

Volatility

UFP Industries, Inc.’s last day, last week, and last month’s average volatility was 0.85%, 1.06%, and 0.38%, respectively.

UFP Industries, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.56%, 3.39%, and 3.45%, respectively.

UFP Industries, Inc.’s Stock Yearly Top and Bottom Value

UFP Industries, Inc.’s stock is valued at $57.96 at 13:22 EST, below its 52-week high of $64.20 and way higher than its 52-week low of $29.17.

UFP Industries, Inc.’s Moving Average

UFP Industries, Inc.’s value is higher than its 50-day moving average of $55.17 and higher than its 200-day moving average of $55.52.

2. QCR Holdings, Inc.

12.6% sales growth and 10.66% return on equity

QCR Holdings, Inc., a multi-bank holding company, provides commercial and consumer banking, and trust and asset management services.

QCR Holdings, Inc.’s sales growth this year is anticipated to be 12.5% and 1.4% for next year.

Year-on-year quarterly revenue growth grew by 5.3%, now sitting on 208.6M for the twelve trailing months.

QCR Holdings, Inc.’s sales growth for the next quarter is 12.6%. The company’s growth estimates for the current quarter and the next is a negative 9.8% and 28.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.66%.

Volatility

QCR Holdings, Inc.’s last day, last week, and last month’s average volatility was 2.37%, 0.99%, and 0.30%, respectively.

QCR Holdings, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.77%, 4.14%, and 2.98%, respectively.

QCR Holdings, Inc.’s Stock Yearly Top and Bottom Value

QCR Holdings, Inc.’s stock is valued at $41.02 at 13:22 EST, under its 52-week high of $43.90 and way higher than its 52-week low of $22.39.

QCR Holdings, Inc.’s Moving Average

QCR Holdings, Inc.’s worth is above its 50-day moving average of $38.86 and way higher than its 200-day moving average of $32.50.

3. Analog Devices, Inc.

15.9% sales growth and 10.3% return on equity

Analog Devices, Inc. designs, manufactures, and markets integrated circuits (ICs), algorithms, software, and subsystems that leverage analog, mixed-signal, and digital signal processing technologies.

Analog Devices, Inc.’s sales growth this year is expected to be 11.6% and 7.1% for next year.

Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 5.6B for the twelve trailing months.

Analog Devices, Inc.’s sales growth for the next quarter is 15.9%. The company’s growth estimates for the current quarter and the next is 27.2% and 27.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.3%.

Volatility

Analog Devices, Inc.’s last day, last week, and last month’s average volatility was 0.73%, 1.21%, and 0.34%, respectively.

Analog Devices, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.56%, 3.19%, and 2.04%, respectively.

Analog Devices, Inc.’s Stock Yearly Top and Bottom Value

Analog Devices, Inc.’s stock is valued at $156.74 at 13:22 EST, under its 52-week high of $159.81 and way above its 52-week low of $79.08.

Analog Devices, Inc.’s Moving Average

Analog Devices, Inc.’s value is higher than its 50-day moving average of $143.64 and way above its 200-day moving average of $125.62.

Previous days news about Analog Devices, Inc.

According to Business Insider on Tuesday, 12 January, “Arya also said he likes Microchip Technology Inc. (NASDAQ:MCHP), Analog Devices, Inc. (NASDAQ:ADI) and Texas Instruments Incorporated (NASDAQ:TXN).”

4. Eli Lilly and Company

13.7% sales growth and 131.77% return on equity

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.

Eli Lilly and Company’s sales growth this year is anticipated to be 9.3% and 12.3% for next year.

Year-on-year quarterly revenue growth grew by 4.8%, now sitting on 23.21B for the twelve trailing months.

Eli Lilly and Company’s sales growth for the next quarter is 13.7%. The company’s growth estimates for the ongoing quarter and the next is 35.8% and 13.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 131.77%.

Volatility

Eli Lilly and Company’s last day, last week, and last month’s average volatility was a positive 0.35%, a negative 0.29%, and a positive 0.53%, respectively.

Eli Lilly and Company’s last day, last week, and last month’s high and low average amplitude percentage was 1.35%, 2.66%, and 2.34%, respectively.

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $166.41 at 13:22 EST, under its 52-week high of $173.90 and way above its 52-week low of $117.06.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is higher than its 50-day moving average of $158.00 and above its 200-day moving average of $152.89.

Previous days news about Eli Lilly and Company

According to Business Insider on Monday, 11 January, “Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the FDA has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) for adults with heart failure with reduced ejection fraction. ”

According to Business Insider on Monday, 11 January, “Shares of drug maker Eli Lilly and Company (LLY) are climbing more than 11% Monday morning on the news of FDA accepting supplemental New Drug Application for its type 2 diabetes treatment Jardiance.”

According to MarketWatch on Wednesday, 13 January, “They include Johnson & Johnson at No. 24 , Pfizer at No. 39 and Eli Lilly and Company at No. 87.”

5. Horizon Therapeutics Public Limited Company

34.3% sales growth and 29.59% return on equity

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.

Horizon Therapeutics Public Limited Company’s sales growth this year is expected to be 64.1% and 27.3% for next year.

Year-on-year quarterly revenue growth grew by 89.7%, now sitting on 1.82B for the twelve trailing months.

Horizon Therapeutics Public Limited Company’s sales growth for the next quarter is 34.3%. The company’s growth estimates for the ongoing quarter and the next is 82.1% and 32.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.59%.

Volatility

Horizon Therapeutics Public Limited Company’s last day, last week, and last month’s average volatility was a negative 0.08%, a positive 1.71%, and a positive 0.50%, respectively.

Horizon Therapeutics Public Limited Company’s last day, last week, and last month’s high and low average amplitude percentage was 3.27%, 4.40%, and 3.94%, respectively.

Horizon Therapeutics Public Limited Company’s Stock Yearly Top and Bottom Value

Horizon Therapeutics Public Limited Company’s stock is valued at $79.54 at 13:22 EST, under its 52-week high of $86.67 and way above its 52-week low of $23.81.

Horizon Therapeutics Public Limited Company’s Moving Average

Horizon Therapeutics Public Limited Company’s worth is way above its 50-day moving average of $71.83 and way above its 200-day moving average of $71.27.

6. EPAM Systems, Inc.

13.9% sales growth and 18.86% return on equity

EPAM Systems, Inc. provides digital platform engineering and software development services in North America, Europe, Armenia, Belarus, Kazakhstan, Russia, Ukraine, Asia, and Australia.

EPAM Systems, Inc.’s sales growth this year is anticipated to be 15.1% and 21.5% for next year.

Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 2.57B for the twelve trailing months.

EPAM Systems, Inc.’s sales growth for the next quarter is 13.9%. The company’s growth estimates for the current quarter and the next is 13.2% and 17.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.86%.

Volatility

EPAM Systems, Inc.’s last day, last week, and last month’s average volatility was a positive 2.68%, a negative 1.17%, and a positive 0.22%, respectively.

EPAM Systems, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.07%, 3.41%, and 3.10%, respectively.

EPAM Systems, Inc.’s Stock Yearly Top and Bottom Value

EPAM Systems, Inc.’s stock is valued at $344.53 at 13:22 EST, below its 52-week high of $360.89 and way higher than its 52-week low of $151.97.

EPAM Systems, Inc.’s Moving Average

EPAM Systems, Inc.’s worth is above its 50-day moving average of $335.55 and above its 200-day moving average of $313.49.

LEAVE A REPLY

Please enter your comment!
Please enter your name here